Analysts Issue Forecasts for Urogen Pharma’s Q3 2017 Earnings (URGN)

Urogen Pharma (NASDAQ:URGN) – Jefferies Group cut their Q3 2017 EPS estimates for shares of Urogen Pharma in a research report issued on Wednesday. Jefferies Group analyst M. Andrews now forecasts that the company will post earnings per share of $0.09 for the quarter, down from their previous estimate of $0.17. Jefferies Group currently has a “Buy” rating and a $27.00 target price on the stock. Jefferies Group also issued estimates for Urogen Pharma’s Q4 2017 earnings at ($0.64) EPS, FY2017 earnings at ($1.76) EPS, FY2018 earnings at ($2.37) EPS and FY2019 earnings at ($1.88) EPS.

A number of other analysts have also issued reports on URGN. Cowen and Company initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock. Oppenheimer Holdings, Inc. initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Raymond James Financial, Inc. initiated coverage on Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Urogen Pharma has a consensus rating of “Buy” and a consensus target price of $26.00.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by [[site]] and is the property of of [[site]]. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at [[permalink]].

Urogen Pharma (URGN) opened at 17.72 on Monday. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $20.02. The firm has a 50 day moving average price of $17.84 and a 200-day moving average price of $17.58. The firm’s market capitalization is $230.52 million.

Hedge funds have recently added to or reduced their stakes in the stock. Spark Investment Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $856,000. Menora Mivtachim Holdings LTD. acquired a new stake in Urogen Pharma during the second quarter worth about $2,331,000. LLBH Private Wealth Management LLC acquired a new stake in Urogen Pharma during the second quarter worth about $695,000. Alps Advisors Inc. acquired a new stake in Urogen Pharma during the second quarter worth about $195,000. Finally, Jennison Associates LLC acquired a new stake in Urogen Pharma during the second quarter worth about $3,168,000. 3.59% of the stock is currently owned by hedge funds and other institutional investors.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.